Distinct Whole-Body Movements in Response to Alcohol and Sexual Content in Alcohol Use Disorder

Posturography Approaches: An Insightful Window to Explore the Role of the Brain in Socio-Affective Processes

A significant amount of research has highlighted the importance of a motor component in the brain's processing of emotional, motivational and social information. Posturography has emerged as an interesting way to assess motor correlates associated with this process. In this review, we highlight recent results within the functional context of painful stimulus perception and discuss the interest in broadening the use of posturography to other motivational and societal functional contexts. Although characterized by significant feasibility, the single measurement of the COP's anteroposterior displacement presents limitations for attesting approach-avoidance behavior towards a visual target. Here, we discuss a number of methodological avenues that could go some way towards overcoming these limitations.

Approach-Avoidance Behavior in the Empathy for Pain Model as Measured by Posturography

The interrelation between motor and emotional processes has been a recurrent question since several decades in the scientific literature. An interesting experimental technique to explore this question is posturography which assess the modulation of human postural control. In an emerging scientific field, this technique has been used to explore the reaction of the body in different emotional conditions. However, among available studies, some inconsistencies appear. In this brief report, we want to show how a widely used experimental model, i.e., empathy for pain, allowed in several study to provide comprehensive understanding elements on the postural correlates of socioemotional information processing. In particular, the role of mental simulation is discussed.

Transcranial direct current stimulation combined with alcohol cue inhibitory control training reduces the risk of early alcohol relapse: A randomized placebo-controlled clinical trial

BACKGROUND

Approximately half of all people with alcohol use disorder (AUD) relapse into alcohol reuse in the next few weeks after a withdrawal treatment. Brain stimulation and cognitive training represent recent forms of complementary interventions in the context of AUD.

OBJECTIVE

To evaluate the clinical efficacy of five sessions of 2 mA bilateral transcranial direct current stimulation (tDCS) for 20 min over the dorsolateral prefrontal cortex (DLPFC) (left cathodal/right anodal) combined with alcohol cue inhibitory control training (ICT) as part of rehabilitation. The secondary outcomes were executive functioning (e.g. response inhibition) and craving intensity, two mechanisms strongly related to abstinence.

METHODS

A randomized clinical trial with patients (n = 125) with severe AUD at a withdrawal treatment unit. Each patient was randomly assigned to one of four conditions, in a 2 [verum vs. sham tDCS] x 2 [alcohol cue vs. neutral ICT] factorial design. The main outcome of treatment was the abstinence rate after two weeks or more (up to one year).

RESULTS

Verum tDCS improved the abstinence rate at the 2-week follow-up compared to the sham condition, independently of the training condition (79.7% [95% CI = 69.8-89.6] vs. 60.7% [95% CI = 48.3-73.1]; p = .02). A priori contrasts analyses revealed higher abstinence rates for the verum tDCS associated with alcohol cue ICT (86.1% [31/36; 95% CI = 74.6-97.6]) than for the other three conditions (64% [57/89; 95% CI = 54-74]). These positive clinical effects on abstinence did not persist beyond two weeks after the intervention. Neither the reduction of craving nor the improvement in executive control resulted specifically from prefrontal-tDCS and ICT.

CONCLUSIONS

AUD patients who received tDCS applied to DLPFC showed a significantly higher abstinence rate during the weeks following rehabilitation. When combined with alcohol specific ICT, brain stimulation may provide better clinical outcomes.

TRIAL REGISTRATION

ClinicalTrials.gov number NCT03447054 https://clinicaltrials.gov/ct2/show/NCT03447054.